Open Nav

Sernova Corp.

  • Philip Toleikis, Sernova Corp.

Raise US investor awareness of our new US Phase I/II Clinical Study for diabetes

  • Date:Thursday, October 18
  • Time:3:00 PM - 3:15 PM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Publicly Traded Company
  • Company Description/Mission Statement:Sernova Corp is developing regenerative medicine therapeutic technologies using an implantable medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body.
  • Company
  • Company HQ City:London
  • Company HQ Country:Canada
  • Company HQ State:Ontario
  • Ticker:SVA.V - SEOVF
  • Exchange:TSX Venture - OTCQB
  • CEO/Top Company Official:Dr. Philip Toleikis
  • Year Founded:2006
  • Main Therapeutic Focus:Regenerative Medicine
  • Lead Product in Development :Cell Pouch™
  • Development Phase of Primary Product:Phase II
Philip Toleikis
Sernova Corp.